发布时间：
Blood purification pharmacokinetics Shanghai Jiaotong University College of Medicine subsidiary Ruijin Hospital kidney Chen Nan-J) N FWR; t Blood purification technology in clinical treatment of acute and chronic renal failure has been nearly half a century, and in critically ill patients, such as acute renal failure (ARF) in the treatment of continuous renal replacement therapy (CRRT) more traditional intermittent hemodialysis greater advantages, its clinical application is gradually expanded from the traditional kidney renal replacement to support development, participate in a multidisciplinary critical severe _ (HwU> Whether or ARF in patients with CRF usually kinds of medication, drugs in the application of these patients should be in accordance with its residual renal function adjustment, and at the same time, blood purification and changed the drug metabolism in patients with these conditions, particularly in critically ill patients, such as failure to consider this factor, medication adjustment programmes, the consequences could be Q: bKT # \ 1) from the following three aspects of the assessment of patients with blood purification P (rS - `I First, the nature of drug j1ZFsTFMWp 1, renal clearance in the proportion of drug: drug in the body's overall clearance rate is the body organ system capacity to remove the sum of drugs, including liver, kidney, as well as other metabolic If drugs mainly through kidney removal, which is usually to remove CRRT part of the in vitro clear / removal of the overall ≥ 25 ~ 30%, it is necessary to adjust the Pio ^ 5j hB6 2, protein binding rate: drug free with biological activity and can be removed filtration, plasma protein binding is the high rate of drugs (such as digitalis glycosides drug, warfarin, ) are difficult to remove CRRT Protein binding rate can be affected by many factors, the theoretical value and the actual situation may have some ! A! \ S / x4 3, molecular weight: small molecular diffusion easy to be adopted by dialysis membrane pore, drug removals and molecular size inversely proportional to macromolecules often convection through, unless more than its molecular weight film hole size, or ultrafiltration rate associated with the Most of the molecular weight of less than 500 drug Da, Da little more than Extension of high-flux dialysis membrane and time of removal can be improved 'T [zh # v> S 4, the volume of distribution (Vd): in vivo drug representatives of the extent of the Vd representative of the high rate of drug organizations with high clearance rate is Vd patients with severe and theoretical value can be very different, but there are individual Drug Vd ≤ 1 L / kg easy clearance, ≥ 2 L / kg difficult to be High flow could be higher IHD Vd drug rapidly cleared from plasma, serum concentration decreased, but only in a dialysis drug remove a small part in the two dialysis between plasma concentration will quickly CRRT continued slow clearance high Vd drugs, the process of drug plasma from the organizations to re-distribution, the change in the plasma concentration of ( 9X, Cefaclor 1 25 24-35 25-5 tid not adjusted to 25 sU? "V Cefoperazone 6-5 90 14-20 1-2 q12h thoroughly after delivery without adjustment?,: # 9 Cefuroxime 2 33 13-18 75-5 q8h thoroughly after administration 0 q12h * i? RJH Ceftazidime 2 17 28-4 1-0 q8h 0 1-0 q24-48h YxE bg (Y Amikacin 4-3 <5 22-29 5mg/kg q12h 2 / 3 of the normal 30-70% q12-18h wI! + L & Q Tobramycin 5 <5 22-33 7mg/kg q8h 2 / 3 of the normal 30-70% q12h lC = N: = Mu Ciprofloxacin 3-6 20-40 5 5-75 q12h 25 q12h 2 q12h, $ h (fM8GC Levofloxacin 4-8 24-38 1-5 5 q24h 25-50% 50% + T, H & # Imipenem 1 13-21 17-3 5-0 q6h thoroughly after administration 50 percent - J "qrp Z ^ Vancomycin 6-8 10-50 47-1 5 q6h 5 q48-q24-96h 5% 48h c X: 3 30 4 losartan 50mg qd-q12h unclear hundred percent jq57C)) X 2 Benazepril 22 95 15 10mg qd not 50-75% uw K h Monopril 12 95 15 10mg qd not 100% [T'yc: = Atenolol 7 45-60 5-10 50-100mg qd 25-50mg 50% q48h s ULIrYRA The name of the drug half-life F Ze: co8Mu (H) protein binding 0zw + @ l ` (%) Vd `" a? A 5] k (L / Kg) renal function f) * NX After the normal dose HD ^ fs m6 f)) SUPPLEMENTARY of CRRT j ~ Q) F | i8 Carvedilol 5-8 95 1-2 25-50mg q12-24h not 100 percent [6AHaOhR ' Nifedipine 4-5 97 4 10-20mg q6-8h not 100%> s & XX, w Amlodipine 35-50 95 21 5mg qd not 100 percent 1p8: 1) q Felodipine 10-14 99 9-10 10mg qd not 100% gs? 8Wzh90 * Digoxin 36-44 20-30 5-8 25-5mg qd not 25-75% q36h H4t) + (: D ' Low-molecular-weight heparin 2-0 unclear 06-13 30-40mg bid unclear 100% p "2m9 0IO Warfarin 34-35 99 15 load 10-15 mg of 2-10 mg qd not iHPUmTus not -- Azathioprine 16-1 20 55-8 5-5mg/kg q24h 25mg/kg 75% yq?] V7 ~ Cyclophosphamide 4-5 14-20 5-1 1-5mg/kg qd 1 / 2 dose of 100% Z:! IX ^ q;) n Vincristine 1-5 75 5-11 4mg / sq m unclear 100% I! P4 (3skAB Prednisone 5-5 80 2 5-60mg qd not 100% X x_ tpC? Prednisolone 5-5 80 2 5-60mg qd need 100 percent OZf6/10O / A prednisone 9-0 40-60 2-5 4-48mg qd not 100 percent [@ / /) # 5v Insulin 2-4 5 15 Indefinite not 75% `([R j M` Acarbose 3-9 15 32 50-200mg tid unclear avoid / 'ZKST4 Effects of Fluvastatin small 5-1 98 42 2-10mg qd unclear 100% k O1)? DWpa Simvastatin 2> 95 mg qd unclear 5-40 unclear 100%
国家级就是，主办单位是是国家级的期刊。这类期刊大多都会加上中国，中华在名称的最前面。一看便知。
国际移植与血液净化杂志职称论文辅导发表，请联系国际移植与血液净化杂志 论文网。国际移植与血液净化杂志操作流程:作者投稿→双方商谈版面费用→作者支付定金→我们送杂志社审稿→作者修改补充稿件→审稿通过（杂志社邮寄用稿通知或给杂志社打电话查稿）→作者支付剩余版面费用→杂志社按期刊登并给作者邮寄样刊（操作流程仅供参考，具体情况请与本人联系！）。医学类论文投稿邮箱：
冠以“中华。。。”字样的，属于中华人民共和国卫生部主办的或委托办的医学类期刊均是国家级的核心期刊。比如:中华医学、中华外科学、中华病理学。。。，祝你心想事成！
HNO HERZ IRBM B-ENT CUTIS PFLEGECHIRURGIN VIVOIN VIVOJBR-BTR NOTARZT给你一些四区的IF<1的医学SCI期刊，你自己琢磨下
首先，登录中国期刊全文数据库、万方数据库或者 维普数据库（此为中国三大专业文献数据库）或国外Pubmed/Medline等国外专业数据库，然后搜索相关的文献，写出您的文章。其次，再去以上数据库中搜索相关专业期刊编辑部信息（国家级或是非国家级，核心或者非核心，统计源或者非统计源期刊等等），找到投稿联系方式，这样的方法避免网上很多钓鱼网站，确保您投稿的期刊是合法的。最后,祝好运。欢迎交流。静石医疗，竭诚为您服务。
国家级就是，主办单位是是国家级的期刊。这类期刊大多都会加上中国，中华在名称的最前面。一看便知。
该杂志如何投稿
国家级就是，主办单位是是国家级的期刊。这类期刊大多都会加上中国，中华在名称的最前面。一看便知。
该杂志如何投稿
国际移植与血液净化杂志职称论文辅导发表，请联系国际移植与血液净化杂志 论文网。国际移植与血液净化杂志操作流程:作者投稿→双方商谈版面费用→作者支付定金→我们送杂志社审稿→作者修改补充稿件→审稿通过（杂志社邮寄用稿通知或给杂志社打电话查稿）→作者支付剩余版面费用→杂志社按期刊登并给作者邮寄样刊（操作流程仅供参考，具体情况请与本人联系！）。医学类论文投稿邮箱：
中国血液净化论坛由“中国医院协会血液净化中心管理分会”和“中国医师协会肾脏内科医师分会”共同主办，《中国血液净化》杂志和《国际移植与血液净化杂志》协办，会议以“加强培训、规范管理、科学治疗、不断创新”为主题，领读血液净化领域的实践指南，介绍血液净化领域临床和实验研究的进展，对不同学派观点展开学术争鸣，并针对疑难病例、危重病例和新技术应用进行广泛讨论。会议将邀请国内、外血液净化领域的知名临床专家、管理专家进行专题学术报告，并设立血液净化技师论坛、护理论坛，以传播血液净化领域的医学知识和科学管理理念，加强对医护人员的业务培训，提高本领域的管理和治疗水准。
该杂志如何投稿
《国际移植与血液净化杂志》社是2003-08-21在北京市朝阳区注册成立的集体所有制，注册地址位于北京市朝阳区白家庄路8号。《国际移植与血液净化杂志》社的统一社会信用代码/注册号是9111010575418474XH，企业法人张金保，目前企业处于开业状态。《国际移植与血液净化杂志》社的经营范围是：出版发行《国际移植与血液净化》杂志；利用自有《国际移植与血液净化》杂志发布广告；设计、制作广告；会议及展览服务。（市场主体依法自主选择经营项目，开展经营活动；依法须经批准的项目，经相关部门批准后依批准的内容开展经营活动；不得从事国家和本市产业政策禁止和限制类项目的经营活动。）。在北京市，相近经营范围的公司总注册资本为6166767万元，主要资本集中在 5000万以上 和 1000-5000万 规模的企业中，共2683家。通过爱企查查看《国际移植与血液净化杂志》社更多信息和资讯。
冠以“中华。。。”字样的，属于中华人民共和国卫生部主办的或委托办的医学类期刊均是国家级的核心期刊。比如:中华医学、中华外科学、中华病理学。。。，祝你心想事成！
根据2010年大部分稿的received与accepted的时间差来看，貌似是40-45天
国家级就是，主办单位是是国家级的期刊。这类期刊大多都会加上中国，中华在名称的最前面。一看便知。
国际移植与血液净化杂志职称论文辅导发表，请联系国际移植与血液净化杂志 论文网。国际移植与血液净化杂志操作流程:作者投稿→双方商谈版面费用→作者支付定金→我们送杂志社审稿→作者修改补充稿件→审稿通过（杂志社邮寄用稿通知或给杂志社打电话查稿）→作者支付剩余版面费用→杂志社按期刊登并给作者邮寄样刊（操作流程仅供参考，具体情况请与本人联系！）。医学类论文投稿邮箱：